Participation
This page provides an overview of who can participate in the ENETS NET Database, the applicable participation rules, and practical information on how to join and receive support.
Eligible centres
The ENETS NET Database is open to specialised neuroendocrine neoplasm (NEN) referral centres both within and outside the European framework. Different eligibility requirements and approval procedures apply, as outlined below.
Within the European framework
The following centres are eligible to participate:
- ENETS Centers of Excellence (CoEs) – NEN referral centres certified by ENETS.
- ERN EURACAN-accredited NEN referral centres.
- Nationally accredited or recognised expert NEN centres – centres accredited or recognised by national authorities.
Individual approval for other European centres
European centres that do not hold any of these accreditations or forms of recognition may apply through an individual approval process. To apply:
-
Complete the ENETS DB Centre Eligibility Checklist.
- Submit the completed checklist to the ENETS Database Team.
The ENETS Database Team coordinates the review. Final approval is granted by the ENETS DB Core Group.
Outside the European framework
Selected NEN referral centres outside the European framework may participate in ENETS-approved database studies.
Participation requires:
- An invitation from the study's Principal Investigator (PI).
- Approval by the ENETS DB Core Group
- Compliance with applicable eligibility and governance requirements
How is the European framework defined?
Classification is not based on geography alone. Where a centre’s status is unclear, the ENETS DB Core Group determines whether it falls within the European framework, taking into account its integration into recognised European clinical and scientific structures.
Participating centres
The following 36 centres across 21 countries participate in the ENETS NET Database.
List as of 5 October 2026
| Country | City | Centre | Participating since |
|---|---|---|---|
| Argentina | Buenos Aires | Instituto Alexander Fleming | 2026 |
| Australia | Melbourne | Peter MacCallum Cancer Centre | 2025 |
| Belgium | Egedem | NETwerk, Universitair Ziekenhuis Antwerpen (UZA) | 2023 |
| Leuven | UZ Leuven | 2023 | |
| Brazil | São Paulo | AC Camargo Cancer Center | 2026 |
| Denmark | Copenhagen | Dept. of Nephrology and Endocrinology Neuroendocrine Tumor Center of Excellence, Rigshospitalet | 2024 |
| France | Clichy | Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris | 2024 |
| Lyon | Hospices Civils de Lyon | 2022 | |
| Paris | Hôpital Cochin, Assistance Publique – Hôpitaux de Paris | 2025 | |
| Institut Gustave Roussy | 2023 | ||
| Germany | Lübeck & Kiel | NET-Zentrum UKSH, University Hospital Schleswig-Holstein | 2023 |
| Marburg | NET-Zentrum Marburg, Philipps Universität Marburg / Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg | 2022 | |
| Minden | Zentrum für Neuroendokrine Neoplasien, Johannes-Wesling-Klinikum Minden | 2026 | |
| Greece | Athens | EKPA-LAIKO Center, 1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, General Hospital of Athens | 2022 |
| Hungary | Budapest | 2nd Department of Internal Medicine, Semmelweis University | 2022 |
| Ireland | Dublin | National Centre for Neuroendocrine Tumours, St. Vincent’s University Hospital | 2023 |
| Israel | Jerusalem | Hadassah-Hebrew University Medical Center | 2022 |
| Italy | Milan | European Institute of Oncology IRCCS | 2022 |
| Fondazione IRCCS Istituto Nazionale dei Tumori | 2024 | ||
| Rome | NET Center Roma, Ospedaliero Universitaria Sant’Andrea | 2024 | |
| Japan | Tokyo | National Cancer Center Hospital | 2026 |
| Netherlands | Amsterdam | Antoni van Leeuwenhoek Ziekenhuis | 2024 |
| Rotterdam | Erasmus MC | 2024 | |
| Norway | Bergen | Haukeland University Hospital | 2023 |
| Poland | Gliwice | Narodowy Instytut Onkologii im. Marii Skłodowskiej – Curie – Państwowy Instytut Badawczy | 2024 |
| Katowice | Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia | 2024 | |
| Spain | Barcelona | Fundació Privada Institut d’Investigació Oncològica de Vall-Hebron (VHIO) | 2024 |
| Barcelona | Institut Català d’Oncologia (ICO) | 2025 | |
| Madrid | Fundación de Investigación Biomédica del Hospital 12 de Octubre | 2023 | |
| Sweden | Uppsala | Department of Endocrine Oncology, Uppsala University Hospital | 2024 |
| Switzerland | Bern | Endokrines Tumorboard, Inselspital Bern | 2023 |
| Lausanne | Centre des tumeurs neuroendocrines (TNE), CHUV | 2026 | |
| United Kingdom | London | NETs, King’s College Hospital NHS Foundation Trust | 2023 |
| Manchester | Neuroendocrine Centre of Excellence, The Christie NHS Foundation Trust | 2024 | |
| USA | Atlanta, GA | Emory Winship Cancer Institute | 2026 |
| Rockville, MD | National Cancer Institute (NCI) of the National Institutes of Health (NIH) | 2026 |
Participation rules
General requirements (all centres)
All participating centres must:
- Have a valid collaboration contract / data sharing agreement with ENETS
- Obtain appropriate ethics committee or institutional review board (IRB) approval, in accordance with local regulations
- Ensure compliance with the General Data Protection Regulation (GDPR) and applicable national data protection laws
- Commit to accurate, complete and timely data entry
- Adhere to ENETS quality standards and governance procedures
Additional regulations for non-European centres
In addition to the general requirements, the following rules apply to centres located outside Europe:
- Must be an established NEN referral centre
- Must have authored or co-authored peer-reviewed publications in the field of neuroendocrine neoplasms
- Must agree to ENETS publication rules and quality control procedures
- Participation requires a formal invitation from the Principal Investigator (PI) of the respective ENETS DB study
- Centres are expected to contribute a meaningful number of patients
- Non-European centres cannot act as Principal Investigators for ENETS DB-based studies
- Patient entry is limited to ENETS-approved database studies
- Participation must be approved by the ENETS DB Core Group
- The responsible collaborating investigator must be an ENETS member
Authorship and publication principles
Scientific output arising from the ENETS NET Database follows transparent and fair authorship principles.
- Authorship is based on meaningful scientific contribution, including data provision and study involvement
- Publication models are defined at study level and communicated in advance
- ENETS publication rules apply to all participating centres
Detailed authorship and publication principles are outlined in the ENETS NET Database Terms of Reference.
How to join
Centres interested in participating in the ENETS NET Database are invited to contact the ENETS Office at database@enets.org.
The participation process typically includes:
- Initial contact and eligibility assessment
- Submission of required documentation
- Contracting and ethics approval
- Study-specific approval (where applicable)
- User account setup and onboarding
The ENETS Office will support applicants throughout the evaluation process.